$VMD

VIEMED HEALTHCARE, INC.

Viemed provides home medical equipment and post-acute healthcare services in the United States, focusing on respiratory care, chronic care and women’s health. Its services include respiratory disease management, neuromuscular care, oxygen therapy, in-home sleep testing and sleep apnea treatment, and healthcare staffing and recruitment for third-party healthcare facilities. Viemed serves patients in all 50 states of the United States. Viemed supplies equipment primarily through monthly rentals, including home ventilation devices, BiPAP and CPAP machines, percussion vests and oxygen concentrators. It also sells related supplies and provides breast pumps, lactation equipment and support services. Licensed respiratory therapists provide in-home equipment setup, training, therapy and on-call services. Viemed also earns income from staffing and recruitment services for healthcare institutions and partners. Its principal executive office is in Lafayette, Louisiana.

AlphAI earnings readThird quarter 2026 · NOV 4Viemed Healthcare Announces Third Quarter 2026 Financial ResultsVerdict: solid

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

1
0
0

No SEC Form 4 filings for $VMD in the last 30 days.

See all $VMD insider activity →
Low

Viemed Healthcare Earnings Call Highlights Growth and Guidance

Viemed Healthcare (VMD) reported Q3 record revenue of $80.7M, up 12.2% YoY, and net income of $4.6M, up 32% YoY. Management raised revenue guidance and highlighted growth in sleep and maternal health services, but noted softer margins and audit delays. Adjusted EBITDA was $17.1M, up 6% YoY. The company expects sequential growth in Q4.

Viemed Healthcare Q3 Earnings Call Highlights

VieMed Healthcare (VMD) reported Q3 operating cash flow of $11.5M and free cash flow of $4M. The company expects Q4 improvements in collections and active ventilator patients. Full-year revenue guidance was raised to $316M-$320M, while adjusted EBITDA was narrowed to $64M-$66M. VieMed had $9.7M in cash and $5.3M in borrowings at Q3's end, with a $1M share buyback and $2M term-loan repayment in October.

VMD sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning VMD (VIEMED HEALTHCARE, INC.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.

Recent VMD coverage spans earnings, financial news and corporate actions.

What's driving VMD

AlphAI scores every news story that mentions VMD with an AI model for sentiment and relevance, and aggregates insider trades from VIEMED HEALTHCARE, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $VMD

Score

Viemed Healthcare Q3 Earnings Call Highlights

VieMed Healthcare (VMD) reported Q3 operating cash flow of $11.5M and free cash flow of $4M. The company expects Q4 improvements in collections and active ventilator patients. Full-year revenue guidance was raised to $316M-$320M, while adjusted EBITDA was narrowed to $64M-$66M. VieMed had $9.7M in cash and $5.3M in borrowings at Q3's end, with a $1M share buyback and $2M term-loan repayment in October.

$VMDMedEarnings

VIEMED HEALTHCARE ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS

VIEMED HEALTHCARE, INC. (VMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. VIEMED HEALTHCARE ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS Lafayette, Louisiana (November 4, 2026) Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national provider of technology-enabled, home-based healthcare solutions and chronic disease management, an

Viemed Healthcare Maps Growth in Home Respiratory Care, Sleep and Maternal Health

VieMed Healthcare (VMD) reported less than 10% market penetration in its noninvasive ventilation service, with 25M U.S. COPD patients and 60K Medicare beneficiaries using its services. The company expanded into sleep, oxygen, and maternal health, with sleep therapy revenue up 44% YoY. VieMed completed three acquisitions, expects $317M revenue in 2026, and has no net debt. Management projects adjusted EBITDA of $66M and share repurchases.

$VMDMedAI 8/10

Viemed Healthcare Targets Low-20% Growth as Home Ventilation Opportunity Expands

Viemed Healthcare (NASDAQ: VMD) anticipates low-20% revenue growth in 2026, with projected revenue of $317M and EBITDA of $66M. The company's ventilator business averages $1,050 monthly per rental, with an average patient length of 17 months. Viemed has expanded into sleep therapy, maternal health, and other areas, completing three acquisitions in the past three years. The company has no net debt and has repurchased nearly 700,000 shares. Management sees organic growth and strategic acquisitions

Viemed Healthcare Announces New Share Repurchase Program of Up to 5% of Shares Outstanding – Minichart

Viemed Healthcare reported Q2 2026 revenue of $78.1M (up 24% Y-o-Y) and Adjusted EBITDA of $13.7M. The company announced a new share repurchase program for up to 5% of outstanding shares, following a strong first half with 680,802 shares repurchased. Full-year 2026 guidance is $314M-$320M in revenue and $64M-$68M in Adjusted EBITDA. The company has a strong balance sheet with $10.7M in cash and no net debt as of June 30, 2026.

Related tickers